The Impact of New Data Released at ASH 2022 on the Treatment Landscape of CML and Ph+ ALL

Medical experts open a discussion on treatment management for patients with CP-CML and Ph+ ALL.

Brandon Dyson, PharmD, BCOP, BCPS reviews the goals of treatment in chronic myeloid leukemia and Philadelphia chromosome–positive ALL and discusses how the goals differ from acute phase CML.

Neal Dave, PharmD, explores how the generation of the tyrosine kinase inhibitors (TKIs) play a role in treatment selection.

Experts review the optimal imatinib dosing strategy that is recommended for patients with chronic myeloid leukemia based on the dosing from the IRIS trial.

Brandon Dyson, PharmD, BCOP, BCPS, discusses the newly released 3-year data from the OPTIC trial, including the study design, baseline characteristics, and efficacy.

Brandon Dyson, PharmD, BCOP, BCPS, and Neal Dave, PharmD, explore the unmet needs to address in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive ALL.

Experts review how the rates of tyrosine kinase inhibitor resistance affect treatment options for these populations and how to sequence treatment for these patients.

Brandon Dyson, PharmD, BCOP, BCPS, provides an overview of how tyrosine kinase inhibitor resistance is identified in patients with chronic myeloid leukemia and Philadelphia chromosome-positive ALL.

Brandon Dyson, PharmD, BCOP, BCPS, reviews the challenges in treatment of resistant chronic myeloid leukemia and Philadelphia chromosome-positive ALL.

Neal Dave, PharmD, reviews the therapeutic options considered for patients with a T315I mutation identified during mutational analysis.

Brandon Dyson, PharmD, BCOP, BCPS, explores considerations when selecting the next line of treatment, and the efficacy of omacetaxine and ponatinib as third-line therapy options.

Experts discuss novel agents being evaluated for use as third-line treatment options and provide their closing thoughts on this discussion.